Kornimate/medical-research-clean huggingface dataset:
a study to analyze the impact of treatment with paliperidone palmitate on clinical outcomes and hospital resource utilization in adult participants with schizophrenia in portugal

Conditions: Schizophrenia

Summary: the purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of paliperidone palmitate 1-month formulation treatment.


Eligibility criteria:
inclusion criteria: * must have a confirmed diagnosis schizophrenia according to the international classification of diseases (icd) 9th edition codes, or the correspondent icd-10 codes if applicable * must have been treated with oral antipsychotics (oaps) and who switched to paliperidone palmitate 1-month formulation (pp1m) due to poor adherence, or lack of efficacy (no significant symptom reduction, as judged by the treating physician, at maximum recommended dose of an antipsychotic for 6 weeks), or participants' choice, or unknown reason when the switch has not been clearly justified * had been treated with oaps for at least 12 months prior to switching to pp1m. during the treatment with oaps, dose adjustments were allowed. participants should have been treated with pp1m for at least 4 consecutive months after the switch * must have available information concerning the annual schizophrenia-related hospitalizations before and after initiation of pp1m treatment during the observation period, and with the indication of pp1m initiation in their medical charts * must be being treated at an ambulatory setting at study entry exclusion criteria: * participants with schizophrenia resistant to treatment (tr). tr is defined for the purpose of this study by at least two failed adequate trials with different antipsychotics (at maximal antipsychotic efficacious label dose for 4 to 6 consecutive weeks) * participants that used clozapine as treatment for schizophrenia in any given period prior to or during the observation period, independently of other concomitant psychotropic medication * participants who have participated in a clinical trial during the observation period * participants that switched to pp1m before the 31st of july 2014, that is in the first 6 months after it was available for reimbursement in portugal
bacteriology of surgical site infection following surgery for intestinal failure

Conditions: Surgical Wound Infection; Surgical Site Infection; Bacteria Infection Mechanism; Intestinal Disease; Intestinal Fistula

Summary: this is a prospective observational study of patients undergoing planned surgery for intestinal failure. the aims of the study are: * to prospectively characterise preoperative bacterial populations amongst patients undergoing surgery for intestinal failure * to examine the relationship between preoperative bacteriology and surgical site infection (ssi) in this patient group * to investigate the effect of surgery and surgical site infection on generic and wound specific quality of life measures


Eligibility criteria:
inclusion criteria: * adults aged \>18 year * diagnosis of intestinal failure or enterocutaneous fistula * undergoing elective surgery within st mark's hospital if unit exclusion criteria: * unable or unwilling to provide informed consent * pregnant
a retrospective study of treatment patterns and clinical outcomes in patients with central nervous system tuberculosis

Conditions: Central Nervous System Tuberculosis

Summary: this is a retrospective clinical study to analyze the clinical characteristics, complications, and effects of different treatment options on long-term prognosis in patients with central nervous system tuberculosis. all cases of central nervous system tuberculosis diagnosed between 2016 and 2021 were included in the electronic medical record system of one center, and data such as demographics, hospitalization information, clinical information, laboratory or imaging examinations, treatment plans, and outcomes were collected.


Eligibility criteria:
inclusion criteria: * the patient meets the following criteria 1) or 2) or 3): 1. the discharge diagnosis is central nervous system tuberculosis, refer to the icd-10 code related to central nervous system tuberculosis. 2. the discharge diagnosis was tuberculous meningitis (icd-10: a17.000), or tuberculous cerebrospinal meningitis (icd-10: a17.001), or tuberculous meningoencephalitis (icd-10: a17.803 ), or tuberculous encephalitis (icd-10: a17.804), or tuberculous brain abscess (icd-10: a17.805), or spinal tuberculosis (icd-10: a17.806), or tuberculous encephalitis water (icd-10: a17.807). 3. tuberculous meningitis diagnosed according to the "guidelines for diagnosis and treatment of central nervous system tuberculosis in china (2019 edition)" * age and gender are not limited. exclusion criteria: * patients with no clear diagnosis at discharge. * patients judged by the investigator to be unsuitable for inclusion in this protocol.
metabolic imaging predict histopathologic response to preop chemoxrt for locally advanced rectal ca

Conditions: Rectal Cancer

Summary: in this research study of metabolic imaging in locally advanced rectal cancer, we hope to learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy. ultimately we hope this information will in the future help us predict which patients will benefit from more or less aggressive initial therapy for their rectal cancer.


Eligibility criteria:
inclusion criteria:- you must be diagnosed with locally advanced rectal cancer and have chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a standard treatment approach for this disease. exclusion criteria:- you are ineligible for this study if you are pregnant or under the age of 18 years old.
treadmill exercise in metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the main purpose of this study is to better understand the effects of two types of treadmill exercise programs that include education and/or techniques that may be helpful for exercise among individuals with, or at risk for, metabolic syndrome.


Eligibility criteria:
inclusion criteria: 1. referred by healthcare provider and given medical clearance for moderate-intensity exercise 2. metabolic syndrome, defined as meeting three or more of the following criteria: * obesity or overweight defined as bmi \> 25 * impaired glycemia (fasting blood sugar of ≥ 100 \[5.6 mmol/l\] or glycated hemoglobin \[a1c\] of ≥ 5.7) * increased blood pressure (130/85 mmhg or higher) or if you take medicine for high blood pressure * increased fasting levels of triglycerides (≥ 150 or 1.7 mmol/l) or decreased fasting high-density lipoprotein (hdl) cholesterol (less than 40 mg/dl or 1 mmol/l for men or 50 mg/dl or 1.3 mmol/l for women) or if you take any medicines for dyslipidemia 3. between the ages of 18-65 4. no regular physical activity (≥ 3 or more days per week) for the past 3 months exclusion criteria: 1. contraindications for treadmill exercise determined by their physician (e.g., cardiopulmonary limitations or diagnoses) or other inability to do treadmill exercise (e.g., musculoskeletal restrictions or severe balance impairment) 2. confirmed diagnosis of coronary artery disease 3. confirmed diagnosis of diabetes 4. currently taking a beta blocker or calcium channel blocker medication 5. uncontrolled and untreated hypertension, defined as a resting blood pressure of 150/90 6. confirmed diagnosis of chronic obstructive pulmonary disease or other severe lung dysfunction that may interfere with exercise (e.g., severe asthma) 7. self-reported psychotic disorder 8. current practice of mindfulness mediation or mindful movement (e.g., yoga or tai chi), defined as regular daily practice or \>2 classes or self-guided sessions per week in the past three months. 9. non-english speaking
effect of vaginal douching with betadine before cs for prevention of post operative infections

Conditions: Puerperal Infection

Summary: the present study was a prospective randomized controlled trial in which subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery or received no vaginal preparation

the present study was a prospective randomized controlled trial in which subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery or received no vaginal preparation

Eligibility criteria:
inclusion criteria: * any patient undergoing cs exclusion criteria: * • betadine allegy. * rupture membranes. * accidental hemorrhage. * h/o suggestive chorioamnionitis ; uterine tenderness, offensive vaginal discharge, fever medical disorders as diabetes, hypertension , cardiac or renal diseqases
efficacy of the combination of mindfulness and buteyko techniques for the improvement of poorly controlled asthma.

Conditions: Asthma; Anxiety; Stress

Summary: administration of a combined program for general (mindfulness) and respiratory (buteyko technique) relationship in patients with poorly controlled asthma and anxiety/stress to determine if it provides an improvement in current control and future risk of asthma.

a mindfulness relaxation program and a buteyko technique respiratory rehabilitation program will be administered individually and weekly, in 10 sessions (5 face-to-face and 5 telematic sessions afterwards). patients will be visited 4 times (at inclusion, one month, 6 months and 12 months after the double intervention), where data on asthmatic morbidity, pulmonary function (spirometry), bronchial inflammation (feno) will be collected and some questionnaires will be administered.

Eligibility criteria:
inclusion criteria: * diagnosis of poorly controlled asthma * in treatment with a combination of ics/laba at medium doses * anxiety and/or functional dyspnea * attended in the outpatient consultations of the asthma unit of the pneumology and allergy service of the hospital de la santa creu i sant pau in barcelona exclusion criteria: * severe asthma exacerbation in the last 30 days * severe disabling comorbidity * severe psychiatric illness * inability to complete questionnaires.

Keywords: asthma anxiety stress mindfulness buteyko
scalp cooling to prevent hair loss in patients undergoing stem cell transplantation for multiple myeloma

Conditions: Multiple Myeloma

Summary: this pilot study of scalp cooling with penguin cold caps will examine the effectiveness of scalp cooling to reduce the development of hair loss in 30 participants with multiple myeloma undergoing high-dose chemotherapy with melphalan and autologous peripheral blood stem cell transplant at cedars-sinai medical center. the investigators will also assess the potential impact of hair loss versus the discomfort and inconvenience of the scalp cooling procedure.


Eligibility criteria:
inclusion criteria: * age ≥18 years * ecog performance status ≤2 * confirmed multiple myeloma diagnosis * hair covering ≥75% of scalp on physical exam at screening visit * planning to undergo soc high-dose chemotherapy with melphalan (dose to be used = 140 - 200 mg/m2 (with rounding per csmc guidelines)) followed by an autologous peripheral blood stem cell transplant. * written informed consent obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: * prior or current use of any scalp cooling treatment * hair covering \< 75% of the scalp on physical exam at screening visit. * medical history and concurrent diseases: reynaud's disease, cold sensitivity, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia * current spinal or neck injury that may interfere with the subject's participation for the full duration of the study, in the opinion of the treating investigator * skin conditions such as psoriasis, eczema, malignancy, or other condition on the scalp that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * current use of oxaliplatin * current use of any other investigational agents * contraindication to melphalan
rocuronium vs cis-atracurium: do rocuronium still 'rocks' in coronary artery bypass grafting

Conditions: Neuromuscular Blockade; Postoperative Pulmonary Atelectasis; Postoperative Pulmonary Complication; Coronary Artery Disease; Coronary Artery Bypass Grafting; Hypothermic Cardiopulmonary Bypass

Summary: the current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. however, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. as such, cis-atracurium's organ-independent hofmann elimination could be in favour.


Eligibility criteria:
inclusion criteria: * all patients that undergo general anaesthesia for cabg surgery requiring neuromuscular blockade of either rocuronium or cis-atracurium exclusion criteria: 1. recent history of pulmonary infection four weeks before surgery 2. exposed to both neuromuscular blockade within 24 hours perioperatively 3. patients intubated or on tracheostomies pre-operatively 4. any missing or incomplete data

Keywords: neuromuscular blockade postoperative pulmonary atelectasis postoperative pulmonary complication coronary artery disease coronary artery bypass grafting hypothermic cardiopulmonary bypass rocuronium cis-atracurium
a phase 1b study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of sr419

Conditions: Peripheral Neuropathic Pain

Summary: this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of sr419 in patients with peripheral neuropathic pain

this is a single center, three-period, complete crossover, double-blind, randomised, placebo- and active-controlled study to compare the preliminary efficacy of a single dose of sr419 to placebo and active control in patients with peripheral neuropathic pain. the study also aims to evaluate the safety, tolerability, and pk of single doses of sr419 in patients with peripheral neuropathic pain.

Eligibility criteria:
inclusion criteria: 1. aged ≥18 years at the time of informed consent. 2. be diagnosed as suffering from chronic peripheral neuropathic pain, and specifically phn or dpn. 3. average daily pain over the last week prior to screening to be of at least moderate severity (a score of ≥4 on the 11-point numeric rating scale \[nrs\]) and be of face, limb or torso location. 4. a minimum score of 19 on the pain detect questionnaire. exclusion criteria: 1. being pregnant or lactating at screening or planning to become pregnant (self or partner) at any time during the study. 2. prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality. 3. known or suspected intolerance or hypersensitivity to any of the study drugs, close related compounds, or any of the stated ingredients. 4. participants on controlled-release opioids (e.g., morphine) unless on a stable dose of morphine equivalent dose (assessed by the faculty of pain medicine opioids calculator) of up to and including 60 mg/day, at the discretion of the investigator. participants on instant-release opioids (e.g., codeine, oxycodone) must withhold dosing for 12 hours prior to administration of study drug. 5. positive testing for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c virus (hcv). 6. creatinine clearance as estimated by estimated glomerular filtration rate (egfr) \<60 ml/min. 7. a history of major psychiatric disorder(s).

Keywords: dpn, phn...etc.
protective effects of remote limb ischemic preconditioning on acute cerebral infarction

Conditions: Stroke

Summary: stroke is one of the three leading causes of human death, and a major cause of adult disability. our pre-clinical studies confirmed that ischemic preconditioning can prevent cerebral infarction. animal studies confirmed that ischemic postconditioning can reduce infarct size of cerebral infarction. investigators hypothesized that postconditioning would reduce infarct volume of ischemic stroke patients.

this study explored the neuroprotective effects of post-positioning on ischemic stroke patients with randomized, double-blinded and controlled method. patients are divided into experimental and placebo groups to receive remote ischemic post-conditioning for 30 days. remote ischemic post-conditioning is performed by the inflating tourniquets to certain extents on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days. it is 200mmhg for ripc group and 60mmhg for control group. evaluation parameters include crp, tnf-α, icam-1 and gfap in blood at 0, 3, 7, 15 and 30 days after treatment; and mri at 0 and 30 days after treatment.

Eligibility criteria:
inclusion criteria: 1. age between 40 to 80 years 2. ischemic cerebrovascular disease within 6 hours 3. national institutes of health stroke scale(nihss) score 0-15,and modified rankin scale(mrs) score 0-4 4. cranial ct to rule out the the cerebral hemorrhage 5. written informed consent was exclusion criteria: 1. cerebral hemorrhage 2. other parts of the active bleeding disease 3. atrial fibrillation 4. moyamoya disease or vasculitis 5. hereditary disease, such as with cadasil, fabry, mitochondrial myopathy 6. out coagulation disorder 7. severe lesions of severe liver and kidney disease, malignancy or other systemic 8. cannot tolerate blipc or without informed consent
adherence to medication in patients with acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: every day, patients present to emergency department due to acute heart failure. there are many causes for decompensation. one possible cause is a lack of adherence to heart failure medication (prognosis-improving medications and diuretics). the aim of this study is to directly measure adherence in patients with acute heart failure (gold standard of adherence measurement using liquid chromatography coupled to high-resolution mass spectrometry= lc-hrms/ms) at the emergency department. questionnaires are used to investigate possible factors influencing adherence.

several drugs has been shown to improve survival and to reduce the risk for hospitalization for acute heart failure (ahf) in patients with chronic heart failure. despite optimal drug treatment, patients with heart failure suffer one hospitalization for ahf every year on average with the requirement of intravenous diuretics. hence, ahf is one of the leading causes for emergency department visits in elderly patients. a possible cause for ahf in patients with known heart failure is nonadherence to drug treatment. long-term-adherence to drugs of chronic diseases is low. direct methods to assess adherence like the measurement drug levels or metabolites in body fluids are considered as the gold standard. this study aimed to i) provide (direct measured) adherence rates of patients presented with ahf to the emergency department and ii) to identify patient-related factors with impact on adherence.

Eligibility criteria:
inclusion criteria: * age ≥18 years of age * known chronic heart failure irrespective of ejection fraction (heart failure with reduced, mildly reduced, or preserved ejection fraction) * requirement of intravenous diuretics (outpatient or stationary treatment) * stable heart failure medication \>2 weeks * ≥1 sign of volume overload (peripheral edema, jugular venous distension, pulmonary rales, ascites, or demonstration of pulmonary venous congestion on chest x-ray) * elevated natriuretic peptides (n-terminal pro brain natriuretic peptide= nt-pro-bnp ≥125 pg/ml) exclusion criteria: - not able to give written informed consent

Keywords: acute decompensated heart failure adherence emergency department
computer-assisted treatment of urinary tract infection in emergency departments and community health centers

Conditions: Urinary Tract Infections

Summary: our study aims to test the utility of computer-assisted treatment for uncomplicated, recurrent urinary tract infections (utis) for women receiving care in safety net health care facilities. as of november 2009, we are also testing the utility of computer-assisted treatment for certain types of complicated cystitis (i.e. women with voiding symptoms and one of the following complicating symptoms: fever, flank pain, or symptoms greater than 7 days).

an english version of the uti kiosk module was validated at ucsf urgent care clinic in 2005, and has been successfully integrated into the clinical work flow at this clinic for over 2 years. the computer-based module is housed in a freestanding kiosk with a touch-screen monitor and audio handset to allow patients with low literacy and minimum computer skills to complete the module. a printer in the kiosk provides a summary of the patient's responses to each question in the module, as well as a prescription for the clinic physician to sign and return to the patient. it's important to emphasize that the computer only "fast-tracks" women who will be treated with antibiotics. all other women see the provider as usual. also, all women who are eligible for computer treatment may opt to see a provider instead.

Eligibility criteria:
inclusion criteria: * female * 18-64 years old exclusion criteria: * below 18 or above 64 * male * new flank pain * severe vomiting * high blood sugar or diabetes * surgery on kidneys * chronic kidney disease * previous cancer or chemotherapy * hiv or aids * pregnant or suspected pregnancy

Keywords: uti kiosk computer assisted care cystitis
study to evaluate safety of vitamin d receptor activators in patients ages 0 to 16 with chronic kidney disease stage 5 receiving peritoneal dialysis within current clinical practice

Conditions: Secondary Hyperparathyroidism; End-Stage Renal Disease

Summary: the objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (shpt). participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).

investigators were free to determine the appropriate therapy for each participant based on clinical judgment. decisions to prescribe paricalcitol or calcitriol were made independently prior to enrollment of participants in this observational study.

Eligibility criteria:
inclusion criteria: 1. male or female between 0 to 16 years of age (inclusive), on peritoneal dialysis for at least 30 days. 2. the patient has a history of secondary hyperparathyroidism as defined by having initiated a vitamin d receptor activator to treat an elevated parathyroid hormone level. 3. the patient is attending a site associated with north america pediatric renal trials and collaborative studies (naprtcs) dialysis registry. 4. patient and the patient's parent or legal guardian must voluntarily sign and date an informed consent and/or assent, approved by the local independent ethics committee/institutional review board, prior to the initiation of any screening or study-specific procedures. 5. patient has received paricalcitol or calcitriol for a minimum of 10 days. exclusion criteria: 1. patient is scheduled for a kidney transplant within 3 months. 2. patient is expected to stop peritoneal dialysis within 3 months. 3. patient is expected to transfer to hemodialysis within 3 months. 4. patient is planning to be enrolled in an investigational study where the drug and/or dose are unknown to the investigator within the first 3 months from the date of patient enrollment.

Keywords: evaluating incidence of hypercalcemia in pediatric patients